Chronic activation of neurokinin-1 receptor induces pulmonary hypertension in rats

被引:15
作者
Chen, LW [1 ]
Chen, CF [1 ]
Lai, YL [1 ]
机构
[1] Natl Taiwan Univ, Coll Med, Dept Physiol, Taipei, Taiwan
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 1999年 / 276卷 / 05期
关键词
neurokinin-1; antagonist; tachykinins; pulmonary arterial pressure; right heart hypertrophy; cardiac output;
D O I
10.1152/ajpheart.1999.276.5.H1543
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In this study we explored the hypothesis that chronic activation of neurokinin-1 (NK-1) receptor induces pulmonary hypertension in Wistar rats. First, the activation of NK-1 receptor on the pulmonary circulation was investigated by use of a chronic injection of NK-1 agonist [Ser(9),Met(O-2)(11)]-substance P (1 x 10(-9) mol/kg) for 2 wk at Sea level (rats breathed room air) and during hypoxia (rats were placed in a hypobaric 380-Torr chamber). Second, we studied the effect of NK-1 antagonist (CP-96345) on developing and developed (after 4 wk of chronic hypoxia) pulmonary hypertension. Pulmonary arterial pressure, the weight ratio of right ventricle to left ventricle + septum, hematocrit, and substance P (SP) were measured. We found that NK-1 agonist significantly increased pulmonary arterial pressure in the sea-level but not in the hypoxic group. However, NK-1 agonist induced neither right heart hypertrophy nor polycythemia. CP-96345 significantly decreased pulmonary arterial pressure in the hypoxic group but had no effect in the sea-level group. Furthermore, CP-96345 significantly attenuated the acute SP-induced increase in pulmonary arterial pressure in the sea-level and hypoxic groups, with a larger increase in the hypoxic group. These results suggest that chronic activation of NK-1 receptor induces pulmonary hypertension and that there is an increase in the sensitivity of pulmonary vessels in response to SP in chronically hypoxic rats.
引用
收藏
页码:H1543 / H1551
页数:9
相关论文
共 39 条
[1]   RELEASE OF SUBSTANCE-P FROM GUINEA-PIG TRACHEA LEUKOTRIENE-D4 [J].
BLOOMQUIST, EI ;
KREAM, RM .
EXPERIMENTAL LUNG RESEARCH, 1990, 16 (06) :645-659
[2]   ROLES OF NEUTRAL ENDOPEPTIDASE IN AIRWAYS [J].
BORSON, DB .
AMERICAN JOURNAL OF PHYSIOLOGY, 1991, 260 (04) :L212-L225
[3]   Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension [J].
Brett, SJ ;
Gibbs, JSR ;
Pepper, JR ;
Evans, TW .
THORAX, 1996, 51 (01) :89-91
[4]   The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats [J].
Chen, SJ ;
Chen, YF ;
Opgenorth, TJ ;
Wessale, JL ;
Meng, QC ;
Durand, J ;
DiCarlo, VS ;
Oparil, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1997, 29 (06) :713-725
[5]   HA1004, AN INTRACELLULAR CALCIUM-ANTAGONIST, SELECTIVELY ATTENUATES PULMONARY-HYPERTENSION IN NEWBORN LAMBS [J].
CROWLEY, MR ;
FINEMAN, JR ;
SOIFER, SJ .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1994, 23 (05) :806-813
[6]   PROTECTION FROM O-2 TOXICITY BY PREEXPOSURE TO HYPOXIA - LUNG ANTIOXIDANT ENZYME ROLE [J].
FRANK, L .
JOURNAL OF APPLIED PHYSIOLOGY, 1982, 53 (02) :475-482
[7]  
GOERRE S, 1995, CIRCULATION, V91, P359
[8]   Efficacy of CI-1020, an endothelin-A receptor antagonist, in hypoxic pulmonary hypertension [J].
Haleen, S ;
Schroeder, R ;
Walker, D ;
Quenby-Brown, E ;
Welch, K ;
Hallak, H ;
Uprichard, A ;
Keiser, J .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1998, 31 :S331-S335
[9]   CHRONIC EDRF INHIBITION AND HYPOXIA - EFFECTS ON PULMONARY CIRCULATION AND SYSTEMIC BLOOD-PRESSURE [J].
HAMPL, V ;
ARCHER, SL ;
NELSON, DP ;
WEIR, EK .
JOURNAL OF APPLIED PHYSIOLOGY, 1993, 75 (04) :1748-1757
[10]  
HARRISON NK, 1995, AM J PHYSIOL, V268, pL268